Hey, I got that call, too. It was from a guy named Robert Johnson, who, oddly, had a very heavy Indian accent.
I won't, but your post does make a valuable point that (I think) many investors do not appreciate. When you buy a stock, you should have an exit strategy in mind. If you are happy with a 30% return, and you get it, congratulations on a good investment. I wonder how many other investors, or traders, have a clear exit point in mind??
That's pretty incredible. That is about a 100x increase over, say, a month ago, when it would have traded about half a million shares in 2 days.
There was a JNJ article on SA yesterday that referred to the Sandoz positive recommendation. It mentioned a company called Epirus Biopharm that has a remicade biosimilar. I am not familiar with the company (yet), but they were up 28% yesterday...presumably because of the FDA AdComm recommendation.
The vote from the FDA Advisory Committee yesterday was certainly good news, and the whole biotech area is up big today, but...
Up 3 points yesterday and up another 2.5 points today, for an overall 32% gain (since Tuesday's close of 16.84; currently at 22.25) is way ahead of the sector.
I'm not complaining though!!
Sentiment: Strong Buy
What do you mean by "found money"? Because I LOST some money (45 cents a share, to be exact) back on December 11. You don't suppose it could be the same money, do you?
You must know that no one can accurately answer your question. "The Market" has a set of assumptions built-in, related to future sales, future profit, future dividends, future of the development portfolio, etc. The stock will move (up or down) as indicators or facts are shared that make "The Market" either change its assumptions or its confidence in the assumptions.
I am a long-time long and HOPE the stock returns to yearly gains, based on developing its portfolio successfully. I don't think any one piece of information will cause a turnaround. What we really need is a string of positive data (eg - new approvals, new progressions of drugs through the pipeline, new management?, new deals, etc)
I speculated last month that the company's early November statement implied early December, rather than "late December". I still think that the company believed, at that time, that the results would be available before the last week of December. The only valid reason to change my view is based on facts or statements from the company. The only relevant fact is the results are not yet available. I have not seen any statement from the company that suggests a delay into next year. My conclusion is that, based on all available information, the results will be made public by Dec 31. Anything else is speculation, unless/until the company updates the date.
so, you're saying that "bad data" are material, but "good data" are not? There is no plausible defense of your comments.
Volume is heavy (for this stock), but I'm not sure what to make of the fact that only about 2.5 million dollars has changed hands on a stock with a market cap of 200 million. Good news (I think), but not sure what's behind it.
I believe AstraZeneca finalized the development and has commercialized Cubicin. i wonder why they did not offer (maybe they did?) to buy the follow-up compound, or the whole company.
As for our buyout, just be patient. When the time, and return are right, it will happen.
what was it about "the way that it traded" that suggests news is coming on Monday? It doesn't look to me any different that it did yesterday.
Wait, it WAS just Tuesday. Ouch! BOHICA